Articles producció científica> Medicina i Cirurgia

Lung Cancer Management with Silibinin: A Historical and Translational Perspective

  • Datos identificativos

    Identificador: imarina:9220620
    Autores:
    Verdura, SaraCuyas, ElisabetRuiz-Torres, VeronicaMicol, VicenteJoven, JorgeBosch-Barrera, JoaquimMenendez, Javier A.
    Resumen:
    The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel anti-cancer therapeutic. Here, we review the historical developments that have laid the groundwork for the evaluation of silibinin as a chemopreventive and therapeutic agent in human lung cancer, including translational insights into its mechanism of action to control the aggressive behavior of lung carcinoma subtypes prone to metastasis. First, we summarize the evidence from chemically induced primary lung tumors supporting a role for silibinin in lung cancer prevention. Second, we reassess the preclinical and clinical evidence on the effectiveness of silibinin against drug resistance and brain metastasis traits of lung carcinomas. Third, we revisit the transcription factor STAT3 as a central tumor-cell intrinsic and microenvironmental target of silibinin in primary lung tumors and brain metastasis. Finally, by unraveling the selective vulnerability of silibinin-treated tumor cells to drugs using CRISPR-based chemosensitivity screenings (e.g., the hexosamine biosynthesis pathway inhibitor azaserine), we illustrate how the therapeutic use of silibinin against targetable weaknesses might be capitalized in specific lung cancer subtypes (e.g., KRAS/STK11 co-mutant tumors). Forthcoming studies should take up the challenge of developing silibinin and/or next-generation silibinin derivatives as novel lung cancer-preventive and therapeutic biomolecules.
  • Otros:

    Autor según el artículo: Verdura, Sara; Cuyas, Elisabet; Ruiz-Torres, Veronica; Micol, Vicente; Joven, Jorge; Bosch-Barrera, Joaquim; Menendez, Javier A.;
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Joven Maried, Jorge
    Palabras clave: Stat3 Silymarin Silibinin Sencar mouse skin Non-small cell lung cancer Multidrug-resistance Milk thistle Metastasis Lysyl oxidase Histone deacetylase Growth-inhibition Factor-kappa-b Epithelial-mesenchymal transition Emt Drug-resistance Acquired-resistance
    Resumen: The flavonolignan silibinin, the major bioactive component of the silymarin extract of Silybum marianum (milk thistle) seeds, is gaining traction as a novel anti-cancer therapeutic. Here, we review the historical developments that have laid the groundwork for the evaluation of silibinin as a chemopreventive and therapeutic agent in human lung cancer, including translational insights into its mechanism of action to control the aggressive behavior of lung carcinoma subtypes prone to metastasis. First, we summarize the evidence from chemically induced primary lung tumors supporting a role for silibinin in lung cancer prevention. Second, we reassess the preclinical and clinical evidence on the effectiveness of silibinin against drug resistance and brain metastasis traits of lung carcinomas. Third, we revisit the transcription factor STAT3 as a central tumor-cell intrinsic and microenvironmental target of silibinin in primary lung tumors and brain metastasis. Finally, by unraveling the selective vulnerability of silibinin-treated tumor cells to drugs using CRISPR-based chemosensitivity screenings (e.g., the hexosamine biosynthesis pathway inhibitor azaserine), we illustrate how the therapeutic use of silibinin against targetable weaknesses might be capitalized in specific lung cancer subtypes (e.g., KRAS/STK11 co-mutant tumors). Forthcoming studies should take up the challenge of developing silibinin and/or next-generation silibinin derivatives as novel lung cancer-preventive and therapeutic biomolecules.
    Áreas temáticas: Saúde coletiva Química Pharmacology & pharmacy Pharmaceutical science Molecular medicine Medicina ii Interdisciplinar Farmacia Drug discovery Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Chemistry, medicinal Biotecnología Biodiversidade
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: jorge.joven@urv.cat
    Identificador del autor: 0000-0003-2749-4541
    Fecha de alta del registro: 2024-07-27
    Volumen de revista: 14
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.mdpi.com/1424-8247/14/6/559
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Pharmaceuticals. 14 (6):
    Referencia de l'ítem segons les normes APA: Verdura, Sara; Cuyas, Elisabet; Ruiz-Torres, Veronica; Micol, Vicente; Joven, Jorge; Bosch-Barrera, Joaquim; Menendez, Javier A.; (2021). Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 14(6), -. DOI: 10.3390/ph14060559
    DOI del artículo: 10.3390/ph14060559
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2021
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Chemistry, Medicinal,Drug Discovery,Molecular Medicine,Pharmaceutical Science,Pharmacology & Pharmacy
    Stat3
    Silymarin
    Silibinin
    Sencar mouse skin
    Non-small cell lung cancer
    Multidrug-resistance
    Milk thistle
    Metastasis
    Lysyl oxidase
    Histone deacetylase
    Growth-inhibition
    Factor-kappa-b
    Epithelial-mesenchymal transition
    Emt
    Drug-resistance
    Acquired-resistance
    Saúde coletiva
    Química
    Pharmacology & pharmacy
    Pharmaceutical science
    Molecular medicine
    Medicina ii
    Interdisciplinar
    Farmacia
    Drug discovery
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Chemistry, medicinal
    Biotecnología
    Biodiversidade
  • Documentos:

  • Cerca a google

    Search to google scholar